Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Second Line Systemic Treatments Including Extracorporeal Photopheresis Among Patients with Chronic Graft Versus Host Disease (cGVHD) in the United States, 2009-2016

Namita Joshi, PhD MS, BPharm, Linlin Luo, MSc, Xingyue Huang, PhD, Ghaith Mitri, MD, Belinda Lovelace, PharmD, An Pham, PharmD, MBA, FAHA, Xin Gao, PhD

Blood (2017) 130 (Supplement 1): 4490.

https://doi.org/10.1182/blood.V130.Suppl_1.4490.4490

Published: 2017

Journal Articles

Tyrosine Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia: Single US Center Experience

H Jean Khoury, Leonard T Heffner, Jr., MD, Martha Arellano, MD, Anand P Jillella, MD, Vamsi K Kota, MD, Elliott F. Winton, MD

Blood (2015) 126 (23): 4045.

https://doi.org/10.1182/blood.V126.23.4045.4045

Published: 2015

Journal Articles

Dasatinib Once-Daily Dose Regimen Provides Robust Anti-Leukemic Activity While Avoiding Suppression of T Cell Activation.

Gary L Schieven, Rosemary Zhang, Sidney Pitt, Kelly McGlinchey, Krista Menard, Richard Smykla, Vojkan Susulic, Mei-Li Wen, Amy Wiebesiek, Robert Townsend, Francis Y. Lee

Blood (2009) 114 (22): 2198.

https://doi.org/10.1182/blood.V114.22.2198.2198

Published: 2009

Journal Articles

Prevention of Rat Cardiac Allograft Rejection by Host Th2 Cell Adoptive Transfer

Shoba Amarnath, PhD, Hao Chen, MD, PhD, Carliann M Costanzo, Joanna M Swerczek, LVT, LATg, Michael A Solomon, MD, Daniel H Fowler, MD

Blood (2008) 112 (11): 365.

https://doi.org/10.1182/blood.V112.11.365.365

Published: 2008

Journal Articles

Durable Responses to Lenalidomide (Revlimid®) in Patients with AL Amyloidosis: Follow Up of a Phase II Trial.

David C. Seldin, MD, PhD, Michael Rosenzweig, MD, Kathleen T. Finn, RN, NP, Salli Fennessey, Anthony Shelton, Jerome B. Zeldis, MD, Martha Skinner, MD, Vaishali Sanchorawala, MD

Blood (2007) 110 (11): 192.

https://doi.org/10.1182/blood.V110.11.192.192

Published: 2007

Journal Articles

Targeted Depletion and Inhibition of Activated T Lymphocytes with SGN-70, a Humanized Antibody Specific for the Activation Antigen CD70.

Julie A. McEarchern, PhD, Kerry Klussman, B.S., Tamar E. Boursalian, Ph.D., Iqbal S. Grewal, Ph.D., Che-Leung Law, Ph.D.

Blood (2006) 108 (11): 1728.

https://doi.org/10.1182/blood.V108.11.1728.1728

Published: 2006

Journal Articles

Argatroban for Anti-Coagulation during Plasma Exchange in a Patient with Cardiac Transplant Rejection and HIT.

Edahn J. Isaak, MD, Gretchen S. Johns, MD, Brenda A. Yamnitz, RN, Tammie A. Keith, RN, Colette Wagner-Mann, MD, Pierantonio Russo, MD

Blood (2004) 104 (11): 4119.

https://doi.org/10.1182/blood.V104.11.4119.4119

Published: 2004

NARROW

Second Line Systemic Treatments Including Extracorporeal Photopheresis Among Patients with Chronic Graft Versus Host Disease (cGVHD) in the United States, 2009-2016

Tyrosine Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia: Single US Center Experience

Dasatinib Once-Daily Dose Regimen Provides Robust Anti-Leukemic Activity While Avoiding Suppression of T Cell Activation.

Prevention of Rat Cardiac Allograft Rejection by Host Th2 Cell Adoptive Transfer

Durable Responses to Lenalidomide (Revlimid®) in Patients with AL Amyloidosis: Follow Up of a Phase II Trial.

Targeted Depletion and Inhibition of Activated T Lymphocytes with SGN-70, a Humanized Antibody Specific for the Activation Antigen CD70.

Argatroban for Anti-Coagulation during Plasma Exchange in a Patient with Cardiac Transplant Rejection and HIT.

Email alerts

ASH Publications

American Society of Hematology

Second Line Systemic Treatments Including Extracorporeal Photopheresis Among Patients with Chronic Graft Versus Host Disease (cGVHD) in the United States, 2009-2016

Tyrosine Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia: Single US Center Experience

Dasatinib Once-Daily Dose Regimen Provides Robust Anti-Leukemic Activity While Avoiding Suppression of T Cell Activation.

Prevention of Rat Cardiac Allograft Rejection by Host Th2 Cell Adoptive Transfer

Durable Responses to Lenalidomide (Revlimid®) in Patients with AL Amyloidosis: Follow Up of a Phase II Trial.

Targeted Depletion and Inhibition of Activated T Lymphocytes with SGN-70, a Humanized Antibody Specific for the Activation Antigen CD70.

Argatroban for Anti-Coagulation during Plasma Exchange in a Patient with Cardiac Transplant Rejection and HIT.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only